Literature DB >> 3881959

Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

D B Haughey, C J Kraft, G R Matzke, W F Keane, C E Halstenson.   

Abstract

A rapid ultrafiltration technique was used to measure the free (unbound) fraction of disopyramide in serum obtained from 14 normal volunteers, 6 chronic hemodialysis patients, and 10 renal transplant recipients. The disopyramide-free fraction varied more than tenfold at a corresponding total (free plus bound) serum disopyramide concentration of 3 micrograms/ml and was related to the concentration of an acute-phase protein, alpha-1-acid glycoprotein (AAG), in patient serum. Moreover, disopyramide-free fraction values were nearly twofold lower than normal in serum specimens obtained from those renal patients and transplant recipients with corresponding AAG serum concentrations greater than 100 mg/100 ml. AAG concentrations varied tenfold in patient serum and were on average nearly three times higher than AAG concentrations in normal volunteer serum. These findings suggested that the free fraction of disopyramide and possibly other drugs which bind extensively to AAG may be lower, and the interpatient variability in drug binding may be much more pronounced in serum obtained from hemodialysis patients and transplant recipients than previously recognized.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881959     DOI: 10.1159/000166900

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  16 in total

1.  Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein.

Authors:  R C Parish; C Spivey
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Pharmacokinetics of quinine in patients with chronic renal failure.

Authors:  P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

4.  Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

Authors:  L E Pedersen; J Bonde; N A Graudal; N V Backer; J E Hansen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

5.  Influence of continuous ambulatory peritoneal dialysis on serum alpha 1-acid glycoprotein concentration and drug binding.

Authors:  F M Belpaire; E J Van de Velde; N H Fraeyman; M G Bogaert; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Disposition of roxithromycin in patients with normal and severely impaired renal function.

Authors:  C E Halstenson; J A Opsahl; M H Schwenk; J M Kovarik; S K Puri; I Ho; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.